Asset Publisher

null Hospital San Cecilio group (Granada)

Hospital Universitario San Cecilio (Granada)


The Hospital San Cecilio group was started in 2000 and joined RIS in 2004 as a clinical associate group and upgraded to a core group in 2012. The group is actively involved in research on viral resistance in Spain in the field of HIV and hepatitis C. At the national level, the group co-coordinates the WP of resistance & subtypes of the RIS, actively participates in GEHEP (Spanish Group for the Study of Hepatitis-SEIMC), is leading clinical research on human papillomaviruses, and is also involved in research on microbiome and metagenomics. The group actively participates in international collaborations related to resistance to antivirals and hepatitis C (CHAIN, ART collaboration, PLATO II, Coronet, SPREAD, EucoHIV, Eurocoord, CAPRE, HEPC-Care, Shared). 

    The areas of research in which the group is currently involved are:

  1. Resistance to antiretrovirals: the group leads the research on transmitted drug resistance in CoRIS. At present research is focused on TDR to first line drugs. The group is conducting the surveillance programme on TDR to integrase inhibitors.
  2. Resistance to direct acting antiviral drugs (DAAs) against hepatitis C virus: the group is leading DAA resistance studies in Spain, both at baseline and failures, giving service to many groups from RIS. The group is actively involved in characterising reinfection events, and how to apply phylogenetic analysis tools for this topic, and also to evaluate the introduction of HCV in Spain, its spread across the country, and from Spain to other parts of the world.
  3. Human papillomavirus in HIV patients: the group has a leadership in the evaluation of the efficacy of vaccination against HPV in HIV patients and on clinical and epidemiological studies of HPV in HIV positive patients
  4. Microbiome analysis: the group has numerous collaborations on microbiome analysis related with probiotics, periodontal diseases, digestive diseases, and other areas (trasplant, basic research)

Related Assets


Federico García
Marta Álvarez
Natalia Chueca
Carmen Hidalgo
María Dolores Merida
Ana Belén Pérez
Antonio Sanchez
David Vinuesa

Related Assets

Related Assets


  • One-year calorie restriction impacts gut microbial composition but not its metabolic performance in obese adolescents. 
    Ruiz A, Cerdó T, Jáuregui R, Pieper DH, Marcos A, Clemente A, García F, Margolles A, Ferrer M, Campoy C, Suárez A.  Environ Microbiol. 2017 Apr;19(4):1536-1551. doi: 10.1111/1462-2920.13713. 
  • High prevalence and diversity of HIV-1 non-B genetic forms due to immigration in southern Spain: A phylogeographic approach. 
    Pérez-Parra S, Chueca N, Álvarez M, Pasquau J, Omar M, Collado A, Vinuesa D, Lozano AB, Yebra G, García F.  PLoS One. 2017 Oct 30;12(10):e0186928. doi: 10.1371/journal.pone.0186928. eCollection 2017. 
  • Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. 
    Lodi S, Günthard HF, Dunn D, Garcia F, Logan R, Jose S, Bucher HC, Scherrer AU, Schneider MP, Egger M, Glass TR, Reiss P, van Sighem A, Boender TS, Phillips AN, Porter K, Hawkins D, Moreno S, Monge S, Paraskevis D, Simeon M, Vourli G, Sabin C, Hernán MA; HIV-CAUSAL Collaboration*.  AIDS. 2017 Nov 10. doi: 10.1097/QAD.0000000000001692. 
  • fety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM). 
    Hidalgo-Tenorio C, Ramírez-Taboada J, Gil-Anguita C, Esquivias J, Omar-Mohamed-Balgahata M, SamPedro A, Lopez-Ruz M, Pasquau J.  SaAIDS Res Ther. 2017 Jul 18;14:34. doi: 10.1186/s12981-017-0160-0. eCollection 2017. 
  • Risk factors for infection by oncogenic human papillomaviruses in HIV-positive MSM patients in the ART era (2010-2016). 
    Hidalgo-Tenorio C, Gil-Anguita C, Ramírez-Taboada J, Esquivias J, López-Ruz MA, Balgahata OM, Javier-Martinez R, Pasquau J.  Medicine (Baltimore). 2017 Sep;96(39):e8109. doi: 10.1097/MD.0000000000008109. 
  • Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012) 
    Monge, S., Díez, M., Alvarez, M., Guillot, V., Iribarren, JA., Palacios, R., Delgado, R., Jaén, A., Blanco, JR., Domingo, P., Portilla, J., Pérez Elías, MJ., Garcia, F.  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2015. 21 (1), 105.e1 
  • Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults. 
    Alvarez, M, Monge, S, Chueca, N, Guillot, V, Viciana, P, Anta, L, Rodriguez, C, Gomez-Sirvent, J L, Navarro, G, de los Santos, I, Moreno, S, Garcia, F.  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2015. 21 (1), 104.e1 - 5 
  • Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations. 
    Monge, S., Guillot, V., Alvarez, M., Chueca, N., Stella, N., Peña, A., Delgado, R., Córdoba, J., Aguilera, A., Vidal, C., García, F  PloS one. 2014. 9 (3), e90710 
  • uantification of viral loads lower than 50 copies per milliliter by use of the Cobas AmpliPrep/Cobas TaqMan HIV-1 test, version 2.0, can predict the likelihood of subsequent virological rebound to >50 copies per milliliter. 
    Álvarez Estévez M, Chueca Porcuna N, Guillot Suay V, Peña Monge A, García García F, Muñoz Medina L, Vinuesa García D, Parra Ruiz J, Hernández-Quero J, García García F.  Q JOURNAL OF CLINICAL MICROBIOLOGY. 2013. 51 (5), 1555 - 1557 
  • Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class. 
    Monge S, Guillot V, Alvarez M, Peña A, Viciana P, García-Bujalance S, Pérez Elias MJ, Iribarren JA, Gutiérrez F, Itziar Casado M, Garcia F.  CLINICAL MICROBIOLOGY AND INFECTION. 2012. 18 (11), E485 - E490 

Related Assets